ADH1B and hepatocellular carcinoma: believed that ADH1B is a key gene associated with afatinib, whose downregulation correlates with poorer prognosis and immune microenvironment changes in HCC patients, and they suggested ADH1B as a value target, offering a significant method for developing novel therapies for HCC (56).